Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer
Status:
Recruiting
Trial end date:
2030-05-31
Target enrollment:
Participant gender:
Summary
China with high incidence of non-small cell lung cancer. In the past few decades, surgery,
radiotherapy, chemotherapy and other treatments were continuously improved, however, the
mortality of lung cancer patients was not significantly decreased. For patients with locally
advanced lung cancer, direct surgery is not effective. It is difficult to achieve radical
resection by surgery merely, and even if many patients receive surgery, they may eventually
have tumor recurrence and poor survival rate. Therefore, it is necessary to explore effective
perioperative neoadjuvant treatment to reduce the risk of postoperative recurrence and
improve the postoperative survival rate of patients. According to the reports, PD-1/ PD-L1
immunocheckpoint inhibitor may become a new method for the treatment of lung cancer.
Preliminary clinical results showed that immunotherapy combined with chemoradiotherapy
provided a synergies antitumor effect. Multiple clinical results showed that serplulimab
provided higher overall response rate for advanced lung cancer. However, in patients with
locally advanced lung cancer, the efficacy of serplulimab combined with chemotherapy for
sequential radical surgery is still unclear. The purpose of this study is to observe and
evaluate the efficacy and safety of serplulimab combined with chemotherapy in the neoadjuvant
therapy of resectable non-small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University